Eli Lilly scoops up Houston biotech startup in $300 million deal (opens original article in a new tab)

Eli Lilly acquired Houston biotech startup CrossBridge Bio for up to $300 million, with clinical trials for its primary ADC candidate expected this year. The deal follows CrossBridge's $10 million seed round and support from TMC Venture Fund and other investors.

• Eli Lilly acquired CrossBridge Bio for up to $300 million.
• CrossBridge's ADC candidate CBB-120 is set for FDA-approved clinical trials this year.
• CrossBridge received $10 million in seed funding and support from TMC Venture Fund and other investors.